《新股消息》綠竹生物(02480.HK)明起招股 入場費近8,414元
內地生物技術公司北京綠竹生物技術-B(02480.HK)公布招股詳情,計劃於全球發行1,038.6萬股H股,當中香港公開發售部分佔一成,國際配售部分佔九成。
每股招股價將介乎32.8至41.65元,每手200股計入場費約8,413.95元。綠竹生物將於明日(25日)起招股,周五(28日)中午截止,預期於5月8日上市,獨家保薦人為中金公司。是次招股將引入嘉實國際投資(Harvest Global Capital Investments)為基石投資者,認購2,000萬美元等值股份。
公司主要從事創新型人類疫苗和治療性生物製劑開發研究,在研產品共7款,當中3款處於臨床階段,包括用於治療帶狀皰疹的核心產品重組疫苗LZ901。首席財務官兼全球資本市場負責人張輝表示,LZ901的中國二期臨床試驗預期將在今年第二季完成,擬於明年首季在美國啟動二期臨床試驗。公司有計劃與擁有強大銷售和營銷網絡的跨國製藥公司合作,在美國及東南亞等海外市場推進LZ901的全球性快速商業化。
按發售價中位數每股37.23元計,是次上市將籌集淨額約2.84億元,當中約58.2%將主要用於核心產品LZ901的臨床開發、製造及商業化;約22.1%用於K3臨床開發及製造;約16.1%用作珠海商業生產設施建設開支;其餘約3.6%為營運資金及一般用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.